Bruker (NASDAQ:BRKR) Given New $75.00 Price Target at Citigroup

Bruker (NASDAQ:BRKR) had its price objective decreased by Citigroup from $80.00 to $75.00 in a report released on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the medical research company’s stock.

Other analysts have also issued research reports about the company. Barclays dropped their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday. The Goldman Sachs Group reduced their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. TD Cowen cut their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday. Finally, Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Stock Performance

BRKR traded down $2.76 during midday trading on Wednesday, reaching $57.73. The company’s stock had a trading volume of 1,077,386 shares, compared to its average volume of 1,072,928. Bruker has a twelve month low of $54.55 and a twelve month high of $94.86. The stock has a market cap of $8.74 billion, a P/E ratio of 23.95, a PEG ratio of 2.32 and a beta of 1.20. The company has a fifty day simple moving average of $63.64 and a 200 day simple moving average of $66.32. The company has a current ratio of 1.65, a quick ratio of 0.75 and a debt-to-equity ratio of 1.18.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The business had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s revenue for the quarter was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.74 EPS. Research analysts expect that Bruker will post 2.61 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BRKR. Marshall Wace LLP increased its position in shares of Bruker by 127.8% during the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Bruker during the second quarter valued at $36,472,000. AQR Capital Management LLC boosted its stake in Bruker by 123.6% during the second quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock valued at $35,444,000 after buying an additional 307,021 shares during the period. Vaughan Nelson Investment Management L.P. lifted its stake in shares of Bruker by 78.3% in the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 593,091 shares of the medical research company’s stock valued at $37,845,000 after acquiring an additional 260,363 shares during the last quarter. Finally, Point72 Europe London LLP increased its holdings in Bruker by 262.9% during the 2nd quarter. Point72 Europe London LLP now owns 333,997 shares of the medical research company’s stock valued at $21,312,000 after purchasing an additional 241,959 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.